Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 27, Issue , 2016, Pages v50-v57

  Lordick, F ^a   Mariette, C ^b   Haustermans, K ^c   Obermannova R ^d   Arnold, D ^e  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d MASARYK UNIVERSITY   (Czech Republic)

^e Instituto CUF de Oncologia (ICO)   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER SURVIVOR; CHEMORADIOTHERAPY; ESOPHAGUS CANCER; FOLLOW UP; HISTOPATHOLOGY; HUMAN; METASTASIS POTENTIAL; MOLECULAR BIOLOGY; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 84995743760     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw329     Document Type: Article

References (41)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer Incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-1403.
2. Castro C, Bosetti C, Malvezzi M et al. Patterns and trends in esophageal cancer mortality and incidence in Europe (1980-2011) and predictions to 2015. Ann Oncol 2014; 25: 283-290.
3. Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med 2014; 371: 2499-2509.
4. El-Serag HB, Hashmi A, Garcia J et al. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut 2014; 63: 220-229.
5. Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG clinical guideline: diagnosis and management of Barrett's esophagus. Am J Gastroenterol 2016; 111: 30-50.
6. Hamilton SR, Aaltonen LA (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon, France: IARC Press 2000.
7. Puli SR, Reddy JB, Bechtold ML et al. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol 2008; 14: 1479-1490.
8. Edge SB, Byrd DR, Compton CC et al. (eds). AJCC Cancer Staging Manual, 7th edition. New York, NY: Springer 2010.
9. Kondrup J, Allison SP, Elia M et al. ESPEN guidelines for nutrition screening 2002. Clin Nutr 2003; 22: 415-421.
10. Weimann A, Braga M, Harsanyi L et al. ESPEN guidelines on enteral nutrition: surgery including organ transplantation. Clin Nutr 2006; 25: 224-244.
11. Mariette C, Gronnier C, Duhamel A et al. Self-expanding covered metallic stent as a bridge to surgery in esophageal cancer: impact on oncologic outcomes. J Am Coll Surg 2015; 220: 287-296.
12. Pech O, Bollschweiler E, Manner H et al. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Ann Surg 2011; 254: 67-72.
13. Cao Y, Liao C, Tan A et al. Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract. Endoscopy 2009; 41: 751-757.
14. Hulscher JB, Van Sandick JW, De Boer AG et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl Med 2002; 347: 1662-1669.
15. Mariette C, Piessen G, Briez N et al. Oesophagogastric junction adenocarcinoma: which therapeutic approach? Lancet Oncol 2011; 12: 296-305.
16. Mariette C, Piessen G. Oesophageal cancer: how radical should surgery be? Eur J Surg Oncol 2012; 38: 210-213.
17. Biere SS, van Berge Henegouwen MI, Maas KW et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 2012; 379: 1887-1892.
18. Mariette C, Meunier B, Pezet D et al. Hybrid minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicenter, open-label, randomized phase III controlled trial, the MIRO trial. J Clin Oncol 2015; 33 2015; 33 (January 20 Suppl.): abstr 5.
19. Birkmeyer JD, Siewers AE, Finlayson EV et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346: 1128-1137.
20. Markar SR, Karthikesalingam A, Thrumurthy S, Low DE. Volume-outcome relationship in surgery for esophageal malignancy: systematic review and meta-analysis 2000-2011. J Gastrointest Surg 2012; 16: 1055-1063.
21. Brusselaers N, Mattsson F, Lagergren J. Hospital and surgeon volume in relation to long-term survival after oesophagectomy: systematic review and meta-analysis. Gut 2014; 63: 1393-1400.
22. Sjoquist KM, Burmeister BH, Smithers BM et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-692.
23. Kranzfelder M, Schuster T, Geinitz H et al. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg 2011; 98: 768-783.
24. Ronellenfitsch U, Schwarzbach M, Hofheinz R et al. Preoperative chemo(radio) therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer 2013; 49: 3149-3158.
25. Allum WH, Stenning SP, Bancewicz J et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27: 5062-5067.
26. Mariette C, Dahan L, Mornex F et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol 2014; 32: 2416-2422.
27. Markar SR, Gronnier C, Pasquer A et al. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study. Eur J Cancer 2016; 56: 59-68.
28. Conroy T, Galais MP, Raoul JL et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 2014; 15: 305-314.
29. Minsky BD, Pajak TF, Ginsberg RJ et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-1174.
30. Markar S, Gronnier C, Duhamel A et al. Salvage surgery after chemoradiotherapy in the management of esophageal cancer: is it a viable therapeutic option? J Clin Oncol 2015; 33: 3866-3873.
31. van Hagen P, Hulshof MC, van Lanschot JJ et al. Preoperative chemoradiotherapy foresophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084.
32. Shapiro J, van Lanschot JJ, Hulshof MC et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015; 16: 1090-1098.
33. Stahl M, Stuschke M, Lehmann N et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-2317.
34. Bedenne L, Michel P, Bouché O et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25: 1160-1168.
35. Stahl M, Walz MK, Stuschke M et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851-856.
36. Klevebro F, Alexandersson von Döbeln G, Wang N et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol 2016; 27: 660-667.
37. Homs MY, Steyerberg EW, Eijkenboom WM et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet 2004; 364: 1497-1504.
38. Smyth EC, Verheij M, Allum W et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (Suppl 5): v38-v49.
39. Dutton SJ, Ferry DR, Blazeby JM et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol 2014; 15: 894-904.
40. Lordick F, Ott K, Krause BJ et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. LancetOncol 2007; 8: 797-805.
41. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.